A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia

Blood

Volumn 116, Issue 13, 2010, Pages 2205-2214

  Niewerth, Denise ^a   Creutzig, Ursula ^b   Bierings, Marc B ^c   Kaspers, Gertjan J L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CARDIOTOXICITY; CATARACT; CHEMOTHERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; COGNITIVE DEFECT; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; GROWTH DISORDER; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HORMONE DEFICIENCY; HUMAN; INFECTION COMPLICATION; INFERTILITY; INTERSTITIAL PNEUMONIA; LIVER VENOOCCLUSIVE DISEASE; METASTASIS; NEUROLOGICAL COMPLICATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 77957696189     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-261800     Document Type: Review

References (49)

1. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005;19(12):2025-2029. (Pubitemid 41741594)
2. Michel G, Rocha V, Chevret S, et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood. 2003;102(13):4290-4297.
3. Bleakley M, Lau L, Shaw PJ, Kaufman A. Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. Bone Marrow Transplant. 2002;29(10):843-852.
4. Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19(12):2130-2138.
5. Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia. 2005;19(12):2101-2116.
6. Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia. 2005;19(12):2054-2062.
7. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97(1):56-62. (Pubitemid 32061242)
8. Heritier SR, Gebski VJ, Keech AC. Inclusion of patients in clinical trial analysis: the intention-totreat principle. Med J Aust. 2003;179(8):438-440.
9. Horan JT, Alonzo TA, Lyman GH, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol. 2008;26(35):5797-5801.
10. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica. 2007;92(11):1519-1532.
11. Pession A, Rondelli R, Basso G, et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia. 2005;19(12):2043-2053.
12. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19(12):2030-2042.
13. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24(27):4499-4506. (Pubitemid 46646248)
14. Reinhardt D, Kremens B, Zimmermann M, et al. No improvement of overall-survival in children with high-risk acute myeloid leukemia by stem cell transplantation in 1st complete remission [abstract]. Blood. 2006;108(11):Abstract 320.
15. Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents. http://www.clinicaltrials.gov/ct2/show/ NCT00111345. Accessed March 10, 2009.
16. Alonzo TA, Wells RJ, Woods WG, et al. Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era. Leukemia. 2005;19(6):965-970.
17. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008;111(3):1044-1053.
18. Phase III Randomized Study of Conventional Combination Chemotherapy With Versus Without Gemtuzumab Ozogamicin in Young Patients With Newly Diagnosed Acute Myeloid Leukemia. http://www.cancer.gov/clinicaltrials/COG-AAML0531. Accessed March 31, 2009.
19. Kardos G, Zwaan CM, Kaspers GJ, et al. Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia. 2005;19(12):2063-2071. (Pubitemid 41741598)
20. Entz-Werle N, Suciu S, van der Werff ten Bosch J, et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia. 2005;19(12):2072-2081.
21. Perel Y, Auvrignon A, Leblanc T, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia. 2005;19(12):2082-2089.
22. Michel G, Leverger G, Leblanc T, et al. Allogeneic bone marrow transplantation vs aggressive postremission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant. 1996;17(2):191-196. (Pubitemid 26057306)
23. Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2 (Elam02). http://clinicaltrials.gov/ct2/show/NCT00149162. Accessed February 11, 2009.
24. Lie SO, Abrahamsson J, Clausen N, et al. Long-term results in children with AML: NOPHO-AML Study Group-report of three consecutive trials. Leukemia. 2005;19(12):2090-2100.
25. NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia. http://www.clinicaltrials.gov/ct2/show/NCT00476541. Accessed February 12, 2009.
26. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med. 1996;334(22):1428-1434.
27. Becton D, Dahl GV, Ravindranath Y, et al. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood. 2006;107(4):1315-1324. (Pubitemid 43242364)
28. Ribeiro RC, Razzouk BI, Pounds S, Hijiya N, Pui CH, Rubnitz JE. Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. Leukemia. 2005;19(12):2125- 2129.
29. Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia. http://www.clinicaltrials.gov/ct2/show/NCT00186966. Accessed February 2, 2008.
30. Tomizawa D, Tabuchi K, Kinoshita A, et al. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Pediatr Blood Cancer. 2007;49(2):127-132.
31. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27(24):4007-4013.
32. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol. 1998;101(1):130-140.
33. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118(2):385-400. (Pubitemid 34994639)
34. Slats AM, Egeler RM, van der Does-van den Berg A, et al. Causes of death-other than progressive leukemia-in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia. 2005;19(4):537-544. (Pubitemid 40521157)
35. Watson M, Wheatley K, Harrison GA, et al. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer. 1999;86(7):1231-1239.
36. Zittoun R, Suciu S, Watson M, et al. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant. 1997;20(4):307-315.
37. Leahey AM, Teunissen H, Friedman DL, Moshang T, Lange BJ, Meadows AT. Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia. Med Pediatr Oncol. 1999;32(3):163-169. (Pubitemid 29095974)
38. Leung W, Hudson MM, Strickland DK, et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol. 2000;18(18):3273-3279.
39. Parsons SK, Gelber S, Cole BF, et al. Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group Study 8821. J Clin Oncol. 1999;17(7):2144-2152. (Pubitemid 29318847)
40. Goemans BF, Tamminga RY, Corbijn CM, Hahlen K, Kaspers GJ. Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only? Haematologica. 2008;93(9):1418-1420.
41. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl). 2004;13(3):279-287. (Pubitemid 38834460)
42. Barr R, Furlong W, Henwood J, et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol. 1996;14(5):1413-1420.
43. Dufoir T, Saux MC, Terraza B, et al. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplant. 1992;10(4):323-329.
44. Welch HG, Larson EB. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med. 1989;321(12):807-812.
45. Uyl-de Groot CA, Gelderblom-den HJ, Huijgens PC, Willemze R, van Ineveld BM. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands. J Hematother Stem Cell Res. 2001;10(1):187-192.
46. Remberger M, Ringden O. Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents. Transplantation. 2007;84(4):551-554. (Pubitemid 47312170)
47. Creutzig U, Reinhardt D. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-a European view. Br J Haematol. 2002;118(2):365-377.
48. Wheatley K. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-a statistician's view. Br J Haematol. 2002;118(2):351-356.
49. Gravel J, Opatrny L, Shapiro S. The intention-totreat approach in randomized controlled trials: are authors saying what they do and doing what they say? Clin Trials. 2007;4(4):350-356. (Pubitemid 47572267)